Says more shipments “derisks” prior FY guidance. Says new shipment numbers support assertion that COVID is “just another respiratory virus” and is now “endemic.” Says company should expect 2024 and beyond to see $200M-$400M in COVID specifically from COVID-only sales. Comments taken from Morgan Stanley Global Healthcare conference.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on QDEL:
- QuidelOrtho says ‘in really good shape’ from supply chain, launch perspective
- QuidelOrtho sees FY23 adjusted free cash flow at low end of prior guidance
- QuidelOrtho says ‘strategically positioned’ to capitalize on long term trends
- QuidelOrtho cuts FY23 adjusted EPS view to $4.85-$5.30 from $5.15-$5.70
- QuidelOrtho reports Q2 adjusted EPS 26c, consensus 28c